In focus · trending topic

Duchenne muscular dystrophy

62 stories · following the connections

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress

By Nasdaq OMXMar 29, 2017, 11:02 AM UTC

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress

By Nasdaq OMXMar 29, 2017, 11:02 AM UTC

Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMD

By Nasdaq OMXMar 27, 2017, 11:02 AM UTC

Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference

By Nasdaq OMXMar 15, 2017, 11:00 AM UTC

Summit Therapeutics Recognises 10th Annual Rare Disease Day

By Nasdaq OMXFeb 28, 2017, 12:00 PM UTC

Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development

By Nasdaq OMXJan 18, 2017, 12:01 PM UTC

Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development

By Nasdaq OMXJan 18, 2017, 12:01 PM UTC

Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress

By Nasdaq OMXDec 15, 2016, 12:00 PM UTC